Viral testing of 18 consecutive cases of equine serum hepatitis: A prospective study (2014-2018)

Autor: Arvind Kumar, Kara M. Lascola, Joy E. Tomlinson, Jeff Brakenhoff, Katie Delph, Randall W. Renshaw, Lisa E. Fultz, Edward J. Dubovi, Melissa Laverack, Bud C. Tennant, Amit Kapoor, Philip J. Johnson, Thomas J. Divers, Todd C. Holbrook, Elizabeth G. Davis, Rebecca E. Ruby, Sheetal Trivedi, Erica C. McKenzie, Gerlinde R. Van de Walle, Harold C. Schott, Jessica Carter‐Arnold, Emilie Setlakwe, Sandra D. Taylor, Laurie A. Beard
Rok vydání: 2018
Předmět:
Male
horse blood origin biologics
Theiler's disease
Hepacivirus
Standard Article
030204 cardiovascular system & hematology
medicine.disease_cause
Gastroenterology
0403 veterinary science
0302 clinical medicine
Blood product
Prospective Studies
Prospective cohort study
Equine pegivirus
lcsh:Veterinary medicine
biology
Hepatitis A
04 agricultural and veterinary sciences
Hepatitis C
Standard Articles
Liver
Hepatitis
Viral
Animal
Female
medicine.medical_specialty
040301 veterinary sciences
Real-Time Polymerase Chain Reaction
Flavivirus Infections
Parvoviridae Infections
03 medical and health sciences
tetanus antitoxin
Theilovirus
Internal medicine
medicine
Animals
Horses
Hepatitis
General Veterinary
Hepatology
Parvovirus
business.industry
Flavivirus
liver failure
parvovirus
biology.organism_classification
medicine.disease
lcsh:SF600-1100
Horse Diseases
EQUID
business
Zdroj: Journal of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine, Vol 33, Iss 1, Pp 251-257 (2019)
ISSN: 1939-1676
Popis: Background Three flaviviruses (equine pegivirus [EPgV]; Theiler's disease-associated virus [TDAV]; non-primate hepacivirus [NPHV]) and equine parvovirus (EqPV-H) are present in equine blood products; the TDAV, NPHV, and EqPV-H have been suggested as potential causes of serum hepatitis. Objective To determine the prevalence of these viruses in horses with equine serum hepatitis. Animals Eighteen horses diagnosed with serum hepatitis, enrolled from US referral hospitals. Methods In the prospective case study, liver, serum, or both samples were tested for EPgV, TDAV, NPHV, and EqPV-H by PCR. Results Both liver tissue and serum were tested for 6 cases, serum only for 8 cases, and liver only for 4 cases. Twelve horses received tetanus antitoxin (TAT) 4-12.7 weeks (median = 8 weeks), 3 horses received commercial equine plasma 6-8.6 weeks, and 3 horses received allogenic stem cells 6.4-7.6 weeks before the onset of hepatic failure. All samples were TDAV negative. Two of 14 serum samples were NPHV-positive. Six of 14 serum samples were EPgV-positive. All liver samples were NPHV-negative and EPgV-negative. EqPV-H was detected in the serum (N = 8), liver (N = 4), or both samples (N = 6) of all 18 cases. The TAT of the same lot number was available for virologic testing in 10 of 12 TAT-associated cases, and all 10 samples were EqPV-H positive. Conclusions and clinical importance We demonstrated EqPV-H in 18 consecutive cases of serum hepatitis. EPgV, TDAV, and NPHV were not consistently present. This information should encourage blood product manufacturers to test for EqPV-H and eliminate EqPV-H-infected horses from their donor herds.
Databáze: OpenAIRE
Externí odkaz: